Navigation Links
Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations

The once-daily HIV treatment would greatly increase effectiveness for patients, but Gilead Sciences and Merck and Co. have failed to register it

in countries where it is needed most

LOS ANGELES, Sept. 10 /PRNewswire-USNewswire/ -- AIDS Healthcare Foundation (AHF) today called on Gilead Sciences and Merck to immediately register and distribute the three-in-one, once daily lifesaving HIV treatment, Atripla, in developing countries. When Atripla first received approval from the Food and Drug Administration (FDA) in July of 2006, advocates like AHF applauded the production of a single, once-a-day drug as a landmark step in treating HIV. However, since its approval, little progress has been made in expanding the availability of the treatment in the developing world, where only 28% of those in need of treatment were able to access it as of December 2006. Efforts made by AHF to clarify what countries currently can purchase Atripla at the announced $613 per patient per year access price have gone unanswered.

"This treatment is a standard therapy in the United States. It is on the World Health Organization's Essential Medicines List, and is an antiretroviral drug regimen that could greatly benefit patients everywhere while reducing costs in the long term," said Michael Weinstein, AIDS Healthcare Foundation President. "The fact that Gilead and Merck appear to be unable or unwilling to make it available in resource-poor countries is deeply troubling, and causing unnecessary suffering. Gilead and Merck should immediately begin making this treatment available to the rest of the world, or license it out to a generic drug manufacturer, such as Cipla, which already produces a generic version in India, that will. In the instances where the registration process has been initiated such as in the European Union, governments must also recognize their roles and streamline the necessary approval processes to facilitate quick distribution of these lifesaving drugs."

The key value of an all-in-one, one pill per day HIV treatment regimen is the reduced pill burden required for patients. Currently, the most widely used regimen for treatment naive patients consists of a combination of at least two pills taken twice per day, often required to be taken with food and during mid-day hours. Atripla, however, only requires a single pill to be taken once daily without food before bed.

"As we have seen in many of our clinics, pill burden and side effects can be challenging for patients to become accustomed to, and they are among the primary reasons patients do not follow their treatment regimens," said Dr. Homayoon Khanlou, AIDS Healthcare Foundation's Chief of Medicine. "With a complete daily treatment regimen in one pill, the advantage goes much further than simply fewer pills and fewer side effects. The ease of treatment results in improved adherence with more patients taking their medication as prescribed, which greatly increases the effectiveness of treatment. This also results in fewer patients developing resistance to the drugs, and from having to move on to more expensive second-line drugs."

AIDS Healthcare Foundation (AHF) is the nation's largest non-profit HIV/AIDS healthcare, research, prevention and education provider. AHF currently provides medical care and/or services to more than 61,000 individuals in 15 countries worldwide in the US, Africa, Latin America/Caribbean and Asia. Additional information is available at

If you have received this news release in error and do not wish to receive future advisories, or if they should be directed to someone else in your organization, please call (323) 860-5262. Alternatively, you may fax your updated information or your request for removal from our list to (323) 962- 8513 or e-mail

SOURCE AIDS Healthcare Foundation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
3. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
4. Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
5. Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
6. Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
7. The American Liver Foundation Urges Cautious Optimism about CDC Report on Declining Acute Hepatitis Infection Rates
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda ... magnetresonansbilder (MR-bilder) för patienter med multipel ... ett forskningsavtal med SyntheticMR AB för att ... forskningsprojekt på sjukhuset. Med SyMRI kan man ...
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the ... 2016 Building Better Radiology Marketing Programs meeting will showcase some of ... 6, 2016, at Caesars Palace in Las Vegas with a pre-conference session on ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop ... not only fulfilling the needs of advisers and clients but going above and ... providing top-tier customer service. However, there's always room for improvement, which is why ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... the largest, most successful and prominent nonprofit healthcare organizations in the country. They ... involvement with various organizations, and helped advance the healthcare industry as a whole ...
(Date:11/27/2015)... ... 2015 , ... Indosoft Inc., developer and distributor of the ... LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making the ... a version of Asterisk that will receive not only security fixes, but feature ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD ... for diagnostic imaging in the Waterloo region. Using the Ocean Platform, family physicians ... directly from their electronic medical record (EMR) without the need for redundant patient ...
Breaking Medicine News(10 mins):